SAN DIEGO, Aug. 29 /PRNewswire-FirstCall/ -- Halozyme Therapeutics,
Inc. (Amex: HTI), a biopharmaceutical company developing and
commercializing recombinant human enzymes, today announced that it will
present at the Roth 2006 New York Conference to be held at the Westin New
York at Times Square on September 6-7, 2006.
Jonathan Lim, MD, Halozyme's President and Chief Executive Officer,
will present on Thursday, September 7, 2006, at 11:30 a.m. Eastern time
(8:30 a.m. Pacific time) and will discuss the Company's strategic
initiatives, product pipeline and market opportunities.
Interested parties can access a live audio webcast and accompanying
slide presentation via the Internet by visiting the Investor Relations
section of the Company's Web site at http://www.halozyme.com. An archived
presentation will be available on the Web site for 30 days.
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company developing and commercializing
recombinant human enzymes for the drug delivery, palliative care, oncology,
and infertility markets. The company's portfolio of products is based on
intellectual property covering the family of human enzymes known as
hyaluronidases. Halozyme's recombinant human enzymes may replace current
animal slaughterhouse-derived extracts that carry potential risks of animal
pathogen transmission and immunogenicity. The company has received FDA
approval for two products: Cumulase(R), the first and only recombinant
human hyaluronidase for cumulus removal in the IVF process; and Hylenex for
use as an adjuvant to increase the absorption and dispersion of other
injected drugs. The versatility of the first enzyme, rHuPH20, enables
Halozyme to develop the product as a medical device, drug enhancement
agent, and therapeutic drug.
Halozyme Contact Investor Relations Contact
David A. Ramsay Zachary Bryant
Chief Financial Officer Lippert/Heilshorn & Associates
(858) 794-8889 (310) 691-7100
dramsay@halozyme.com zbryant@lhai.com
SOURCE Halozyme Therapeutics, Inc.
 back to top
Related links:
http://www.halozyme.com
CONTACT:
David A. Ramsay, Chief Financial Officer of
Halozyme Therapeutics, Inc., +1-858-794-8889,
dramsay@halozyme.com; or Investor Relations, Zachary Bryant of
Lippert/Heilshorn & Associates, +1-310-691-7100,
zbryant@lhai.com, for Halozyme Therapeutics, Inc.
|
